Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080]
Corresponding Author of This Article
Chung-Tsen Hsueh, MD, PhD, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, 11175 Campus Street, CSP 11015, Loma Linda, CA 92354, United States. chsueh@llu.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 21, 2016; 22(31): 7080-7090 Published online Aug 21, 2016. doi: 10.3748/wjg.v22.i31.7080
Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma
Chung-Tzu Hsueh, Julie H Selim, James Y Tsai, Chung-Tsen Hsueh
Chung-Tzu Hsueh, Department of Dentistry, Cathay General Hospital, Taipei 10630, Taiwan
Julie H Selim, Division of Hematology/Oncology, Loma Linda University Cancer Center, Loma Linda, CA 92350, United States
Julie H Selim, School of Pharmacy, Loma Linda University, Loma Linda, CA 92350, United States
James Y Tsai, Chung-Tsen Hsueh, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92354, United States.
Author contributions: Hsueh CT, Selim JH, Tsai JY and Hsueh CT conceived the issues which formed the content of the manuscript and wrote the manuscript.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Chung-Tsen Hsueh, MD, PhD, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, 11175 Campus Street, CSP 11015, Loma Linda, CA 92354, United States. chsueh@llu.edu
Telephone: +1-909-5588107 Fax: +1-909-5580219
Received: March 30, 2016 Peer-review started: April 6, 2016 First decision: May 30, 2016 Revised: June 13, 2016 Accepted: July 6, 2016 Article in press: July 6, 2016 Published online: August 21, 2016 Processing time: 137 Days and 17.3 Hours
Abstract
Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.
Core tip: The nanovector-based anti-cancer therapeutics play important role in the treatment of advanced pancreatic adenocarcinoma. Data from completed clinical trials are reviewed, and important ongoing studies are presented. Biomarkers for patient selection and personalized medicine are discussed.
